Adolescents and young adults (AYAs) are defined as those individuals between the ages of 15 and 39 years.
A population-based UK study of adolescents with HL diagnosed from January 19981 to December 2000 found a 5 and 10 year OS of 93 and 86 % respectively for the cohort, with an OS for early stage disease of 100 and 91 % respectively. 18 Another study from British Columbia compared the outcomes of adolescents aged 16 to 21 with those of young adults aged 22-45, both age groups having received first-line doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD)-based treatment between 1981 and 2004. 7 There were no significant differences in progression-free survival (PFS) and OS between the two groups, even in advanced-stage disease (10-year PFS and OS of 71 and 88 %, respectively, for advanced-stage adolescents compared to 75 and 86 % for young adults). Among the adolescents, there were no differences in outcomes between those aged 16-18 years and those 19-21 years (PFS, p= 0.25; OS, p=0.44).
The authors discuss the possible bias of a greater number of young patients and those with poor prognostic features entering trials compared to older patients and those with lower risk disease. Indeed many clinical trials focus on those patients with poorer-risk disease. 18 A retrospective study from Athens reported the outcomes of 55 patients diagnosed with HL and aged 16-23 years. 9 Patients were treated with the 14 There were no differences in outcome (OS and EFS) at five and 10 years comparing patients treated on adult and pediatric protocols.
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A subgroup analysis of patients younger than 18 years of age showed an OS of 89.4 ± 4 % at five years and 83.1 ± 6 % at 10 years following adult group therapy, compared with 92.8 ± 3 % and 89.6 ± 3 % following pediatric group therapy (p=0.2822). However, the five-year and 10-year EFS of children younger than 18 years were 69.6 ± 7 % and 59.1 ± 8 %, treated with adult group therapy, compared to 82.4 ± 4 % following pediatric group treatment (p=0.0157). Based on these data, the authors suggest the administration of pediatric protocols in patients younger than 18.
Pooling together the data from the studies that show specific patients' baseline characteristics (histological subtypes, gender, stages, B-symptoms and bulky disease), there were no differences between adolescents and young adults with HL, which strongly suggests similar disease biology in adolescent and young adult patients. 7, 8, 14 Second malignancies (SMs) are considered events in determining EFS.
Only Foltz et al. described the specific types and numbers of solid tumors (STs) among survivors of the study cohort. Three studies reported the specific number of AML/MDS, NHL, and STs.
Combining these data, these SMs occur in 0.65 %, 0.95 %, and 1. 
Pediatric Studies Including Adolescents and Young Adults
There are few studies comparing the outcomes between children and adolescents (see Table 2 ). Excellent results for adolescents have been reported with the OPPA-OEPA/COPP protocols (the agents used in these drug combinations are listed in the note at the bottom of Table 2 ).
The DAL-HD-90 trial reported no difference in OS or EFSamong age groups 15-18 years old versus children younger than 16 years old. 26 In the GPOH-HD-2002 trial, the boys' treatment was changed, with an increment acute lymphoblastic leukemia were 0.9 % for each. 26, 27 In the POG study, with a median follow-up of 5.2 years, three patients developed AML and one osteosarcoma. 28 In the COG study, with a median follow-up of 6.3 years, two patients developed AML.
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Long-term Sequelae
Second Malignancies
The most important late treatment effect among female AYA survivors of HL is BC, which accounts for almost 40 % of diagnosed SMs in this population. 30, 31 Among women treated for HL before the age of 30, the risk of developing BC is six times greater than in the general population, with an absolute excess risk of 20-40 occurrences per 10,000 annually. Comparing BC after HL with de novo BC, the following relevant characteristics in HL survivors are:
• earlier stage at diagnosis, possibly due to recommended screening guidelines for HL survivors;
• increased risk of synchronous or metachronous bilateral BC, secondary to often bilateral radiation exposure, limiting opportunities of breast conserving therapy;
• younger age at diagnosis, thus likely to display a more aggressive phenotype and to be hormone receptor-negative;
• evidence of increased genetic instability in the tumor; and
• increased risk of death from causes other than BC, including a seven-fold increased risk of death from other cancers and a two-to four-fold increased risk of cardiac death.
32,35,36
Hodgkin's Lymphoma in Adolescents and Young Adults Moreover, a study comparing IF-RT and involved nodal radiation therapy (IN-RT) found that the latter produced an average reduction in mean heart dose of 50 % and in breast dose of 42 %. 38 Studies examining the dose-risk relationship for STs suggest a decrease in risk parallel to a dose reduction to less than 40 Gy. 34, [39] [40] [41] It will take at least another decade to study the BC risk associated with contemporary HL treatments, so it may be inappropriate to alarm patients who are scheduled for conformal dose-reduced RT by relating the experience from radical RT given between three and five decades ago. Regardless, it is important to counsel patients on preventive measures, such as smoking cessation and healthy lifestyle modifications. 32, 34, 42 The risk of secondary AML/MDS syndrome is clearly related to the primary CT and is dependent on dose and type of drug. [43] [44] [45] [46] However, a meta-analysis showed increased risk after CT+RT compared with CT only for advanced-stage disease. 47 In a study of eight randomized trials 
Cardiac and Pulmonary Toxicity
The effects of thoracic RT on cardiac risk are difficult to separate from those of anthracyclines because few patients undergo RT without the use of anthracyclines. The pathogenesis of injury differs: radiation primarily affects the fine vasculature of the heart and anthracyclines produce direct damage to the myocytes. 49 The use of IF-RT or IN-RT may reduce the morbidity caused by damage to the valves and the microvasculature within the myocardium, but it is not clear that the risk of coronary artery disease will be substantially reduced among patients receiving mediastinal treatment. 33 Increased risk of anthracycline-related cardiomyopathy is associated with female sex, cumulative doses higher than 200-300 mg/m 2 , younger age at time of exposure, and increased time from exposure. [50] [51] [52] Given that the use of anthracyclines is part of all contemporary protocols, it is plausible that cardiac morbidity may surpass SM as the dominant long-term sequelae among survivors of contemporary HL therapy. 33 
Thyroid Abnormalities
Abnormalities of the thyroid are extremely common in young adult 
Gonadal Toxicity
Gonadal toxicity may manifest as infertility, lack of sexual development, and sexual dysfunction. Infertility caused by azoospermia is the most common manifestation of gonadal toxicity. Some pubertal male patients will have impaired spermatogenesis before they begin therapy. 54 Alkylator CT, especially if containing procarbazine and/or cyclophosphamide, is most harmful to gonadal functioning. At higher cumulative doses, alkylator containing regimens may cause prolonged azoospermia in 90-100 % of men. 55 A few studies have evaluated male fertility following cyclophosphamide-containing regimens given to children and young adults with sarcomas and other cancers [56] [57] [58] and suggest that the incidence of sterility will be low if the cyclophosphamide dose is less than 7.5 g/m 2 . Data concerning ovarian function following CT for female children and young adults with HL suggest that the ovaries of children and adolescents are less sensitive to the effects of alkylating agents than the ovaries of older women; females over 30 years have a much higher risk of acute ovarian failure. However, with long-term follow-up, the cumulative risk of menopause before the age of 40 becomes the same irrespective of treatment age, and the incidence of early menopause in young female survivors may be as high as 37 %. 55, 59, 60 Options for fertility preservation in women receiving cytotoxic therapies are available in some jurisdictions (see, for example, recommendations from the network FertiPROTEKT [available at: www.fertiprotect.eu]).
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Balanced and realistic counseling about fertility prior to the start of therapy is essential. Semen cryopreservation before treatment is started should be offered to all post-pubertal males. imaging. 24 The GHSG HD18-trial stratifies according to PET scans
performed after two cycles of BEACOPP-escalated. The major goal of this currently ongoing study is to show whether the total number of cycles can be reduced from eight to four in patients with negative early interim PET. 62 Similarly, the EuroNet-PHL-C1 trial for children and adolescents with HL is comparing the five-year EFS rate in patients with an adequate response determined by PET after two courses of vincristine, etoposide, prednisone, and doxorubicin (OEPA) who do not receive RT with those patients whose response is such that RT is required. The estimaged target EFS is 90 %. 63 In addition to decreasing the number of patients receiving RT, efforts are aimed at reducing RT fields from currently accepted IF-RT to more recently proposed IN-RT.
However, it will be many years before an associated reduction in late toxicity will be clinically demonstrable. 
Follow-up for Survivors
In order to reduce the morbidity associated with long-term sequelae, shows that many of these survivors have deficient health-related knowledge and are not engaging in the recommended health promotion and screening practices that could improve their long-term outcomes. 65 In a population-based study of AYA survivors, Keegan et al. found that this group of patients has substantial unmet information needs varying according to demographic and health-related factors. 66 More than half of all AYAs had unmet information needs relating to their cancer returning and cancer treatments. They must also contend with a lack of services, either due to financial constraints or inadequate resources from the medical team. The majority of AYAs who needed a pain management expert, a physical and occupational therapist, a mental health worker, or financial advice on how to pay for healthcare did not receive those services. Some AYA patients and survivors are unemployed due to their condition, with the subsequent lack of health insurance and access to appropriate long-term follow-up care.
Psychosocial Problems and Interventions
In a study of young adult cancer survivors, 20 % reported not having visited a cancer center in the past two years. 67 Systematic healthcare transition constitutes the standard of care for AYA survivors of childhood cancer. In developing a transitional care program, it is necessary to consider the scope of services to be provided, the available resources, and other local exigencies that help determine the optimal model for use. 65 Zebrack and Isaacson described the psychosocial interventions likely to reduce distress and promote individuals' ability to cope with stressful conditions -these interventions are detailed below. 68 • Peer support programs offer AYAs opportunities to build interpersonal and problem solving skills, create a sense of community among support group members, and address areas of concern (such as coping with uncertainty about the future, establishing autonomy while dealing with forced dependence on family and friends, social exclusion, body image, sex and sexuality, and infertility). There are reports showing improvements in psychological wellbeing as well as in knowledge, confidence, ability to cope, self-efficacy, and effective interpersonal interactions from group participation.
• Technology-based interventions satisfy AYAs' needs for information and support and have been associated with increased self-efficacy, improved knowledge and enhanced treatment adherence. However, the vast amount of information available on the Internet may cause confusion and AYAs need guidance in how to seek, sift through, and understand this information.
• Skill-based interventions-including problem-solving interventions and cognitive behavioral therapies-teach new skills or induce new ways of thinking, to promote change in one's conditions or circumstances.
The ability to engender trust and to be flexible are key requirements of caregivers who deal with AYA patients. The ability to relate to others is important in winning the trust and respect of the AYA population in particular. Transition times are often unpredictable and thus challenging, but replete with possibility, 69 and the quality of survivorship is critical to any assessment of the quality of treatment.
Conclusions
There is clear evidence to support the treatment of patients aged 16-18 years with pediatric regimens. For HL patients aged 18-21 years the published results are not clearly different and the result of the recently closed pediatric COG protocols in which this patient group is included will be of interest. In general, however, contemporary adult and pediatric treatment regimens have shown excellent survival results with overall reduction of therapy intensity. It is expected that these protocols will result in very different long term toxicity profiles from those described in published studies to date.
In the future, increasingly sophisticated studies will be required to define patients whose therapy can be further reduced without compromising 
